|
1
|
Kumar P and Aggarwal R: An overview of
triple-negative breast cancer. Arch Gynecol Obstet. 293:247–269.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Boyle P: The globalisation of cancer.
Lancet. 368:629–630. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Autier P, Boniol M, LaVecchia C, Vatten L,
Gavin A, Héry C and Heanue M: Disparities in breast cancer
mortality trends between 30 European countries: Retrospective trend
analysis of WHO mortality database. Br Med J. 341:c36202010.
View Article : Google Scholar
|
|
4
|
Bauer KR, Brown M, Cress RD, Parise CA and
Caggiano V: Descriptive analysis of estrogen receptor
(ER)-negative, progesterone receptor (PR)-negative, and
HER2-negative invasive breast cancer, the so-called triple-negative
phenotype: A population-based study from the California cancer
Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carey LA, Dees EC, Sawyer L, Gatti L,
Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou
CM: The triple negative paradox: Primary tumor chemosensitivity of
breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sotiriou C and Pusztai L: Gene-expression
signatures in breast cancer. N Engl J Med. 360:790–800. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kreike B, van Kouwenhove M, Horlings H,
Weigelt B, Peterse H, Bartelink H and van de Vijver MJ: Gene
expression profiling and histopathological characterization of
triple-negative/basal-like breast carcinomas. Breast Cancer Res.
9:R652007. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Krishnamurthy S, Poornima R, Challa VR and
Goud YG: Triple negative breast cancer-our experience and review.
Indian J Surg Oncol. 3:12–16. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sethi S, Sarkar FH, Ahmed Q, Bandyopadhyay
S, Nahleh ZA, Semaan A, Sakr W, Munkarah A and Ali-Fehmi R:
Molecular markers of epithelial-to-mesenchymal transition are
associated with tumor aggressiveness in breast carcinoma. Transl
Oncol. 4:222–226. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Podo F, Buydens LM, Degani H, Hilhorst R,
Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J,
Monleon D, et al: Triple-negative breast cancer: Present challenges
and new perspectives. Mol Oncol. 4:209–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Collins M, Ling V and Carreno BM: The B7
family of immune-regulatory ligands. Genome Biol. 6:2232005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Flajnik MF, Tlapakova T, Criscitiello MF,
Krylov V and Ohta Y: Evolution of the B7 family: Co-evolution of
B7H6 and NKp30, identification of a new B7 family member, B7H7, and
of B7's historical relationship with the MHC. Immunogenetics.
64:571–590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brandt CS, Baratin M, Yi EC, Kennedy J,
Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, et
al: The B7 family member B7-H6 is a tumor cell ligand for the
activating natural killer cell receptor NKp30 in humans. J Exp Med.
206:1495–1503. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu MR, Zhang T, Gacerez AT, Coupet TA,
DeMars LR and Sentman CL: B7H6-specific bispecific T cell engagers
lead to tumor elimination and host antitumor immunity. J Immunol.
194:5305–5311. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang G, Ye Y, Yang X, Liao H, Zhao C and
Liang S: Expression-based in silico screening of candidate
therapeutic compounds for lung adenocarcinoma. PLoS One.
6:e145732011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Elias AD: Triple-negative breast cancer: A
short review. Am J Clin Oncol. 33:637–645. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Herold CI and Anders CK: New targets for
triple-negative breast cancer. Oncology (Williston Park).
27:846–854. 2013.PubMed/NCBI
|
|
19
|
Miller K, Wang M, Gralow J, Dickler M,
Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE:
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic
breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Siziopikou KP and Cobteigh M: The basal
subtype of breast carcinomas may represent the group of breast
tumors that could benefit from EGFR-targeted therapies. Breast.
16:104–107. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Salazar N, Muñoz D, Kallifatidis G, Singh
RK, Jordà M and Lokeshwar BL: The chemokine receptor CXCR7
interacts with EGFR to promote breast cancer cell proliferation.
Mol Cancer. 13:1982014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cui W, Zhang S, Shan C, Zhou L and Zhou Z:
microRNA-133a regulates the cell cycle and proliferation of breast
cancer cells by targeting epidermal growth factor receptor through
the EGFR/Akt signaling pathway. FEBS J. 280:3962–3974. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carey LA, Rugo HS, Marcom PK, Mayer EL,
Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A,
et al: TBCRC 001: Randomized phase II study of cetuximab in
combination with carboplatin in stage IV triple-negative breast
cancer. J Clin Oncol. 30:2615–2623. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Freedman GM, Anderson PR, Li T and
Nicolaou N: Locoregional recurrence of triple-negative breast
cancer after breast-conserving surgery and radiation. Cancer.
115:946–951. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Voduc KD, Cheang MC, Tyldesley S, Gelmon
K, Nielsen TO and Kennecke H: Breast cancer subtypes and the risk
of local and regional relapse. J Clin Oncol. 28:1684–1691. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Leung J and Suh WK: The CD28-B7 family in
anti-tumor immunity: Emerging concepts in cancer immunotherapy.
Immune Netw. 14:265–276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Luo L, Chapoval AI, Flies DB, Zhu G,
Hirano F, Wang S, Lau JS, Dong H, Tamada K, Flies AS, et al: B7-H3
enhances tumor immunity in vivo by costimulating rapid clonal
expansion of antigen-specific CD8+ cytolytic T cells. J Immunol.
173:5445–5450. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Salceda S, Tang T, Kmet M, Munteanu A,
Ghosh M, Macina R, Liu W, Pilkington G and Papkoff J: The
immunomodulatory protein B7-H4 is overexpressed in breast and
ovarian cancers and promotes epithelial cell transformation. Exp
Cell Res. 306:128–141. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Delahaye NF, Rusakiewicz S, Martins I,
Ménard C, Roux S, Lyonnet L, Paul P, Sarabi M, Chaput N, Semeraro
M, et al: Alternatively spliced NKp30 isoforms affect the prognosis
of gastrointestinal stromal tumors. Nat Med. 17:700–707. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fauriat C, Just-Landi S, Mallet F,
Arnoulet C, Sainty D, Olive D and Costello RT: Deficient expression
of NCR in NK cells from acute myeloid leukemia: Evolution during
leukemia treatment and impact of leukemia cells in NCRdull
phenotype induction. Blood. 109:323–330. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu MR, Zhang T, DeMars LR and Sentman CL:
B7H6-specific chimeric antigen receptors lead to tumor elimination
and host antitumor immunity. Gene Ther. 22:675–684. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miyaki M, Iijima T, Konishi M, Sakai K,
Ishii A, Yasuno M, Hishima T, Koike M, Shitara N, Iwama T, et al:
Higher frequency of Smad4 gene mutation in human colorectal cancer
with distant metastasis. Oncogene. 18:3098–3103. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kundu J, Wahab SM, Kundu JK, Choi YL,
Erkin OC, Lee HS, Park SG and Shin YK: Tob1 induces apoptosis and
inhibits proliferation, migration and invasion of gastric cancer
cells by activating Smad4 and inhibiting betacatenin signaling. Int
J Oncol. 41:839–848. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Deckers M, van Dinther M, Buijs J, Que I,
Löwik C, van der Pluijm G and ten Dijke P: The tumor suppressor
Smad4 is required for transforming growth factor beta-induced
epithelial to mesenchymal transition and bone metastasis of breast
cancer cells. Cancer Res. 66:2202–2209. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pohl M, Radacz Y, Pawlik N, Schoeneck A,
Baldus SE, Munding J, Schmiegel W, Schwarte-Waldhoff I and
Reinacher-Schick A: SMAD4 mediates mesenchymal-epithelial reversion
in SW480 colon carcinoma cells. Anticancer Res. 30:2603–2613.
2010.PubMed/NCBI
|
